There were 709 press releases posted in the last 24 hours and 155,020 in the last 365 days.

The Global Market: Bispecific Antibodies for Cancer, Anticipated to Exhibit a CAGR of More Than 30% by 2023

/EIN News/ -- Dublin, May 16, 2019 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibodies for Cancer Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The bispecific antibodies for cancer market will register a CAGR of over 30% by 2023.

The advantages of bispecific antibodies over monoclonal antibodies is one of the key factors expected to propel the market growth during the forecast period.

The limitations of monoclonal antibodies such as limited binding abilities for specific antigens have encouraged researchers to improve and increase the efficacy of the molecules and enhance their function by developing antibodies with two or more targets.

Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy. Hence, the advantages of bispecific antibodies will drive the growth of the market in the upcoming years.

Increasing prevalence of cancer

The increase in the prevalence of cancer across the world will fuel the demand for bispecific antibodies to treat these cancers, thereby driving the growth of the market.

The high cost of drug

Most of the cancer patients in low- and middle-income countries fail to complete the course of drug therapy as these drugs are priced beyond their reach.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Players

  • Amgen Inc.
  • Astella Pharma Inc.
  • Ben Kang Biopharmaceutical (Shenzhen) Co. Ltd.
  • Merus
  • Regeneron Pharmaceuticals Inc.

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: MARKET SEGMENTATION BY TARGET

  • Comparison by target
  • CD19/CD3 - Market size and forecast 2018-2023
  • CD30/CD16A - Market size and forecast 2018-2023
  • Market opportunity by target

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • RoW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors Covered
  • Vendor Classification
  • Market Positioning of Vendors
  • Amgen Inc.
  • Astella Pharma Inc.
  • Ben Kang Biopharmaceutical (Shenzhen) Co. Ltd.
  • Merus
  • Regeneron Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/r/7naeyx

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Oncology Drugs 

22157.jpg


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.